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The role of neutralizing antibodies in prevention
of HIV-1 infection: what can we learn from the
mother-to-child transmission context?
Martine Braibant1* and Francis Barin1,2
Abstract
In most viral infections, protection through existing vaccines is linked to the presence of vaccine-induced
neutralizing antibodies (NAbs). However, more than 30 years after the identification of AIDS, the design of an
immunogen able to induce antibodies that would neutralize the highly diverse HIV-1 variants remains one of the
most puzzling challenges of the human microbiology. The role of antibodies in protection against HIV-1 can be
studied in a natural situation that is the mother-to-child transmission (MTCT) context. Indeed, at least at the end of
pregnancy, maternal antibodies of the IgG class are passively transferred to the fetus protecting the neonate from
new infections during the first weeks or months of life. During the last few years, strong data, presented in this
review, have suggested that some NAbs might confer protection toward neonatal HIV-1 infection. In cases of
transmission, it has been shown that the viral population that is transmitted from the mother to the infant is
usually homogeneous, genetically restricted and resistant to the maternal HIV-1-specific antibodies. Although the
breath of neutralization was not associated with protection, it has not been excluded that NAbs toward specific
HIV-1 strains might be associated with a lower rate of MTCT. A better identification of the antibody specificities that
could mediate protection toward MTCT of HIV-1 would provide important insights into the antibody responses that
would be useful for vaccine development. The most convincing data suggesting that NAbs migh confer protection
against HIV-1 infection have been obtained by experiments of passive immunization of newborn macaques with
the first generation of human monoclonal broadly neutralizing antibodies (HuMoNAbs). However, these studies,
which included only a few selected subtype B challenge viruses, provide data limited to protection against a very
restricted number of isolates and therefore have limitations in addressing the hypervariability of HIV-1. The recent
identification of highly potent second-generation cross-clade HuMoNAbs provides a new opportunity to evaluate
the efficacy of passive immunization to prevent MTCT of HIV-1.
Keywords: HIV-1, Neutralizing antibodies, Mother-to-child transmission, Preventive vaccine, Passive immunization,
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Review
Introduction
UNAIDS estimates that there were 34.0 million people
living with the human immunodeficiency virus (HIV) at
the end of 2011. The development of a safe, effective,
preventive HIV vaccine remains among the highest glo-
bal health priorities. Most vaccines that successfully con-
trol viral diseases induce the production of neutralizing
antibodies (NAbs) that prevent infection. In the case of
HIV-1, a key element for NAbs to be effective in pre-
venting infection is their capacity to neutralize the highly
diverse circulating HIV-1 variants, which can differ by
more than 30% in the sequences of their envelope glyco-
proteins. Encouragement for the development of a NAb-
based anti-HIV-1 vaccine was provided by successful
passive immunization studies in macaque models show-
ing that broadly human monoclonal NAbs administered
orally, vaginally or intravenously could prevent the ac-
quisition of infection [1-10]. Despite the fact that in
some of these experiments, the viral strain used for
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challenge was particularly sensitive to neutralization by
the passively administered NAbs, these results provided
the proof-of-concept that antibodies can block HIV-1 in-
fection. Unfortunately, the capability of vaccine candi-
dates to induce NAbs has turned out to be extremely
complex and disappointing. First attempts to develop
antibody-based anti-HIV-1 vaccines in man involved re-
combinant protein immunogens based on monomeric
forms of the surface-exposed gp120 component of the
envelope glycoprotein (AIDSVAX gp120 B/B and B/E)
[11-13]. High levels of antigen-specific antibodies were
induced in human vaccinees but failed to neutralize most
primary isolates and did not confer protection [14-17].
More recently, the RV144 vaccine trial based on a prime-
boost regimen consisting of a recombinant canarypox
vector prime (ALVAC-HIV) and gp120 protein boost
(AIDSVAX gp120 B/E), showed only moderate protection
in low-incidence heterosexuals [18]. These trials, in a real
life situation, have indicated the limitations of animal
model studies that used only a few selected challenge viral
strains. They also highlighted the probable need to de-
velop more sophisticated envelope immunogens. For this,
lessons from studies aiming at dissecting the antibody re-
sponse during natural infection might be particularly
useful. It has been shown recently that broadly NAbs, de-
veloped after several years of infection by some HIV-1
infected patients, require a high level a somatic mutations
to become broad and potent [19-24]. This suggests that
an effective vaccine may require a combination of various
envelopes to direct B-cell responses through multiple
rounds of antibody maturation and mutation process [25].
Another key question for vaccine development is the iden-
tification of correlates of protection. Indeed, the specificity
and magnitude of the NAbs response required to confer
protection against HIV-1 transmission in humans are still
unclear, and progress in this field is a key step on the road
to an effective HIV-1 vaccine.
Mother-to-child transmission: a model to identify
correlates of protection
Mother-to-child transmission (MTCT) of HIV-1 is cur-
rently the principal cause of HIV infections in children.
Whereas access of HIV pregnant women to antiretroviral
therapy has increased significantly, HIV infection in chil-
dren remains a major concern. In 2011, an estimated
330,000 children were newly infected with HIV (UNAIDS).
Without any antiretroviral treatment, MTCT rate of HIV-1
is around 30 to 40% and occurs mainly at three stages: in
utero during pregnancy (5-10%), perinatally at the time of
labor and delivery (15-20%), and postpartum through
breastfeeding (10-15%) [26-29] (Figure 1). This contrasts
with a much lower rate of MTCT of HIV-2 which, in ab-
sence of antiretroviral treatment, ranges from 0% to 4%
only [30-34]. Despite the high transmission rates of HIV-1,
a large number of children exposed to HIV-1 do not
become infected. Several maternal factors, including low
CD4+ T-cells counts and high viral loads are associated
with an increasing risk of HIV-1 MTCT [35]. The lower
plasma viral load in HIV-2 infected patients, compared to
HIV-1 infected patients, may account for the lower MTCT
risk for HIV-2 [33,34,36-40].
The role of maternal immune response in limiting
HIV-1 transmission to the infant is still unclear. The pla-
centa is relatively impermeable to IgA and IgM, levels of
which are therefore very low in the newborn. In con-
trast, maternal IgG are transported over the placenta by
an active process mediated by the FcRn receptor [41].
The timing of maternal IgG passage across the placenta
during pregnancy was addressed in several studies (for a
review see [42]). During the first trimester, very little IgG
is transmitted to the fetus, but in the second trimester, the
fetal IgG concentration increases from approximately 10%
of the maternal concentration at 17–22 weeks of gestation
to 50% at 28–32 weeks [41,43-45]. During the third
trimester, fetal IgG levels continue to rise, reaching normal
or somewhat exceeding adult levels at term [45-50]
(Figure 1). It was illustrated recently in the HIV-1 context
in a study that showed that the envelope binding antibody
titers were strongly correlated and similar between
mothers and their corresponding infants [51]. MTCT con-
stitutes therefore an attractive model to explore the puta-
tive protecting role of passively acquired HIV-specific IgG
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Figure 1 Infant antibody levels over the three possible stages
(in utero, perinatally or postpartum) of mother-to-child
transmission of HIV-1. During pregnancy, maternal IgG are
transmitted to the fetus across the placenta, reaching normal or
somewhat exceeding adult levels at term. After birth, the IgG
transferred from the mother disappear progressively, while the
amount of IgG being produced by the infant continues to increase.
In contrast, the placenta is relatively impermeable to Ig of other
classes, levels of which are therefore very low in the newborn.
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against HIV acquisition. In the absence of data on the pu-
tative role of NAbs in prevention of MTCT of HIV-2, this
review will focus on HIV-1 infection that has been the
subject of intensive investigations.
Selective transmission of HIV-1 variants from mothers to
infants
The first molecular studies of env sequences diversity is-
sued from infected individuals, adults as well as children,
have shown that most of acute/recent infections are
characterized by the presence of a highly homogenous
genetically-restricted virus population in contrast to the
high genetic diversity observed several years later at time
of chronic infection [52-62]. These observations led
rapidly to the assumption of a substantial bottleneck in
virus transmission (Figure 2A). Recently, the use of sin-
gle genome amplification (SGA) of HIV-1 plasma viral
RNA obtained from acutely infected adult individuals,
allowed the identification of transmitted/early founder
viruses, and the precise estimation of their diversity
[63-67]. These studies showed evidence of infection by a
single virus in ~80% of heterosexuals and ~60% of HIV-
infected men who have sex with men [63,64,66,67]. In
contrast, the frequency of multiple variants transmission
was found to be higher among intravenous (IV) drug
users (~60%), including one subject who was infected by
at least 16 variants [65]. The high frequency of mutiple-
variants transmission in IV drug users could be due to
the absence of a mucosal barrier to virus transmission
and higher virus inocula. To date, such large studies
have not been conducted on samples from children
born to infected mothers. However this question has
been considered using different molecular approaches
(Table 1) (Figure 2B) [61,68-89]. Data vary from one
study to another but all together, comparing the viral
population in mother-child pairs, they showed a homo-
geneous genetically-restricted population in the major-
ity of infected infants (156 of 235; table I), suggesting a
selective transmission of some viral variants during
MTCT (Figure 2B). The lack of consensus among these
studies may be due to the fact that many studies com-
pared only a limited number of mother-child pairs and
did not address the route of transmission (in utero, peri-
natally or postpartum through early breasfeeding). In
A
B
Genetic bottleneck
Transmitted early founder virus
Donor quasispecies
Pair 0540 Pair 1333
Figure 2 Selective transmission of HIV-1. A. The quasispecies of the chronically infected donor is usually composed of a major viral population
(dark blue virions), as well as numerous other minor variants. One of these minor variants (yellow virion) successfully crosses the mucosal barrier
to generate the infection of the recipient. B. The neighbor-joining trees of HIV-1 env gp120 nucleotide sequences issued from two mother-infant
pairs show the transmission of a single maternal viral variant [85]. Bootstrap values are expressed as percentages per 1000 replicates. Only
bootstrap values >50% are indicated. Horizontal branch lengths are drawn to scale, with the black bar denoting 1% divergence. Each symbol
denotes a single env sequence; □, maternal sequence; ●, infant sequence.
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addition, the ages of the infants at time of sample col-
lection varied considerably among studies.
Focusing on transmission through breastfeeding, three
recent studies have shown that there is no or very lim-
ited viral compartmentalization between milk and blood,
suggesting that breast milk viruses are typical of circulat-
ing viruses [90-92]. As with other routes of MTCT, a
genetic bottleneck that restrict the number of variants
transmitted through breastfeeding to a single or a small
number of variants was reported [82].
Several studies examined the molecular characteristics
of the envelope glycoproteins of transmitted viruses that
might explain the selective process. Two studies of
Wolinky’s group, in which MTCT route was not defined,
reported that the potential N-linked glycosylation site
(PNGS) proximal to the first cysteine of the V3 loop
(N295) was strikingly absent from the infant’s sequence
populations but present in the majority of the maternal
sequence sets [61,68]. This observation has not been
found by other investigators [69,70,73,74]. Studies
performed on sequences encoding the full-length gp120
reported shorter variable regions and/or fewer PNGS in
clade A and C viruses transmitted from mother-to-in-
fant, mainly perinatally or early postpartum [81,86,88].
In contrast, we and others did not find altered gp120
length or PNGS number in the clade B and CRF01-AE
viruses transmitted perinatally from mothers to their in-
fants [85,87]. Interestingly enough, similar observations
were reported during or shortly after heterosexual trans-
mission of HIV-1. Transmitted viruses of subtype A and
C showed a more compact and less glycosylated gp120
but this molecular property was not observed for
sexually transmitted viruses of clade B [55,93,94]. This
highlighted potential differences in the biology of the
different subtypes, regardless of their transmission mode.
Although we did not find shorter gp120s or fewer PNGS
in maternally transmitted CRF01-AE viruses, we how-
ever found a limited number of PNGS, N301 in V3 and
Table 1 Studies of the viral population of HIV-1 infected infants
Infant samples
Infection route
Homo-/heterogeneous
population ratio References
Nature Collection time*
Amplified env
region
PBMCs 2 to 4 months V3 and V4-V5 Unspecified 3/0 [61]
PBMCs Unspecified V3 and V4-V5 Unspecified 4/0 [68]
PBMCs and serum 0 to 4 months V3 1 IU, 9 unknown 8 (1 IU)/2 [69]
Serum At birth V3 1 IU 1/0 [70]
PBMCs 0 to 12.5 months V3 1 IU, 4 unknown 2/3 (1 IU) [71]
PBMCs 2 days to 7 weeks V1-V2-C2 Unspecified 1/2 [72]
PBMCs 1 week to 34 months V3 Unspecified 7/0 [73]
PBMCs 5 days to 1.5 months V3 Probably 1 PN, 3 IU 1 (PN)/3 (IU) [74]
PBMCs and plasma 2 to 40 days C2-V3 Unspecified 3/1 [75]
PBMCs 1 month V3 Unspecified 13/4 [76]
Plasma 48 hours or 2 to 6 weeks V3-V5 9 PN, 14 IU 17 (7 PN, 10 IU)/6 (2 PN, 4 IU) [77]
PBMCs 0 or 2 to 6 months C2-V4 3 PN or early PP, 1 IU 3 (2 PN, 1 IU)/1 [78]
PBMCs 0 or 6 weeks V1-V4 7 PN or early PP, 6 IU 6 (2 IU, 4 PN)/7 (4 IU, 3 PN) [79]
PBMCs 48 hours or 2 to 6 weeks V3-V5 7 PN, 14 IU 15 (5 PN, 10 IU)/6 (2 PN, 4 IU) [80]
PBMCs or plasma 6 weeks V1-V5 8 PN or early PP, 1 IU, 3 BF 11/1 (PN) [81]
PBMCs or cord blood 0 or 6 to 15 months V1-V3 3 PP, 1 IU 4/0 [82]
PBMCs 4 to 18 months V1-V5 Unspecified 0/3 [83]
Plasma 0 or 6 weeks V1-V2 23 PN, 25 IU 20 (6 PN, 14 IU)/28 (17 PN, 11 IU) [84]
Plasma 48 hours or 6 weeks V1-V5 11 PN, 6 IU 14 (9 PN, 5 IU)/3 (2 PN, 1 IU) [85]
PBMCs 2 to 4 months V1-V5 6 PN or early PP 5/1 [86]
Plasma 30 to 66 days V1-V5 5 PN 3/2 [87]
Plasma 0 or 6 weeks V1-V5 9 PN or early PP, 10 IU 13 (5 PN, 8 IU)/6 (4 PN, 2 IU) [88]
Plasma 3 or 6 months complete env 2 PP 2/0 [89]
total: 156/235
* Time of the first PCR or coculture positive collected sample after birth.
PN: perinatally; IU: in utero; PP: postpartum through breastfeeding.
Braibant and Barin Retrovirology 2013, 10:103 Page 4 of 14
http://www.retrovirology.com/content/10/1/103
N386 in C3, that seemed to be conserved in all infected
infants but were not uniformly present in their mothers,
suggesting that they may confer an advantage on the
virus to be transmitted [85]. By comparing functional
properties of pseudotyped viruses expressing envelopes
carrying or not N301 and/or N386, we confirmed that
these two PNGS may play a role in resistance to autolo-
gous sera [95]. Interestingly, the N-linked glycan at pos-
ition 301 was recently shown to be important for HIV-1
neutralization by several new broad and potent monoclo-
nal NAbs of the PGT series (PGT125-128, PGT130 and
PGT131) [96]. Similarly, Moore et al. recently reported in
two HIV-1-infected adults the apparition of the N-linked
glycan at position 332 targeted by PGT128, through im-
mune escape from earlier strain-specific antibodies [97]. It
could be possible that NAbs drive viral selection during
MTCT, leading to variants with conserved glycan motifs
that would confer a selective advantage.
Neutralizing antibodies: in search of correlates of protection
in the MTCT context
MTCT offers a unique opportunity to explore the puta-
tive role of NAbs in restricting or preventing infection,
especially when the transmission occurs in presence of
high levels of passively acquired maternal IgG, i.e. during
the perinatal and early breastfeeding periods. Conflicting
results have been obtained concerning the role of maternal
NAbs in reducing MTCT of HIV-1. Early studies, each
relatively small, showed that non-transmitting mothers had
more frequently detected and/or higher titers of autologous
NAbs than transmitting mothers, suggesting a role for
maternal NAbs in reducing MTCT [98-101]. Supporting
this model, a few studies have suggested that transmitted
viruses are escape variants resistant to neutralization by
maternal antibodies [80-82,102,103]. However, other studies
did not confirm these findings [88,89,95,104-106]. The
observed discordant results may be due to small sample
sizes, disparate maternal and infant sample collection time
points, and a lack of identification of the route of transmis-
sion in several studies (in utero, in absence or in presence
of only low levels of IgG, versus perinatally or early post-
partum, in presence of high levels of IgG).
Because transmitted variants were found to be resist-
ant to neutralization by their own mother’s plasma in
several studies, we previously hypothesized that protect-
ive antibodies might be those with a broad neutralizing
activity. To test this hypothesis, we conducted three large
studies, i.e. two studies in Thailand [107,108], and one
study in French patients [109], in which we compared the
breadth and levels of NAbs in sera of transmitting and
non-transmitting mothers, using panels of heterologous
primary isolates of different clades. Our data did not
support an association between the breadth of HIV-1 neu-
tralizing activity and a lower rate of MTCT of HIV-1,
whether transmission occurred in utero or perinatally (the
infants were not breast-fed). Similar results were obtained
by others in Kenyan infants of HIV-1 positive mothers
[110]. All these data clearly indicate that infants who ac-
quired broad and potent NAbs able to neutralize heterol-
ogous HIV-1 variants of different subtypes from their
mothers did not show a reduced risk of infection. How-
ever, our studies suggested that particular HIV-1 variants
might be indicators of NAbs associated with in vivo pro-
tection. Indeed we found that NAbs toward a CRF01-AE
isolate, MBA, were significantly associated with a lower
rate of MTCT in Thailand. Similarly, statistically signifi-
cant higher frequencies or titers of NAbs toward several
strains were observed in non-transmitting mothers in our
French study when the clade B-infected mothers or non
clade-B-infected mothers were analyzed separately [109].
Collectively, these data suggest that particular HIV-1 vari-
ants may provide a measure of protective antibodies de-
pending of the population. These HIV-1 variants may be
particular strains on which epitopes targeted by protective
NAbs would be particularly well exposed in contrast to
those of non-protective antibodies. The identification of
these strains would be dependent of the HIV-1 subtype of
the studied population suggesting that the neutralizing re-
sponse specificities might vary between viral subtypes.
Conducting large studies on homogeneous populations
(in terms of geographical origin, viral clade, maternal viral
loads and antiretroviral prophylaxis) to limit confounding
viral and/or host factors would be necessary to identify
such indicator strains.
The targeted epitope(s) of the neutralizing response
associated with protection was not explored in studies
cited above. To date, only one recent study conducted in
a cohort of South African patients addressed this question
by focusing on the putative role of maternal gp41-specific
antibodies passively transferred to newborns [111]. An as-
sociation of antibodies to the membrane-proximal exter-
nal region (MPER) of gp41 with virus neutralization and
protection was reported. This observation needs to be
confirmed by other studies. More particularly it should be
extended to other important conserved epitopes using
various techniques, such as serum absorption with recom-
binant Env proteins or functional neutralization assay with
various Env-pseudotyped viruses, that have been recently
developed to dissect the neutralizing activity present in
human sera [112-114]. These epitopes, most of them be-
ing of conformational nature, were identified thanks to
the isolation of human monoclonal broadly neutralizing
antibodies (HuMoNAbs) [96,115-118] (Figure 3). They are
conserved regions of the HIV-1 envelope glycoprotein
such as the CD4 binding site (CD4bs) on gp120, quater-
nary structure dependent epitopes on the V1-V2 variable
loops of gp120, glycan-dependent epitopes involving the
V3 region of gp120, and the MPER of gp41. A fine
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comparison of the specificity of the neutralizing response
between transmitting and non-transmitting mothers by
such extensive serum mapping using Env proteins or Env-
pseudotyped viruses derived from HIV-1 strains indicator
of protective antibodies should help to define more pre-
cisely if some antibody specificities correlate with protec-
tion in the MTCTcontext.
In the absence of antiretroviral prophylaxis, HIV is
transmitted via breastfeeding to only 10-15% of infants,
despite daily milk exposure. This suggests that breast milk
may contain antiviral immune factors protecting most
infants from mucosal HIV infections. HIV-1 envelope-
specific antibody responses have been detected in milk.
However, despite a predominance of secretory IgA in
milk, the magnitude of the HIV-1 envelope-specific IgA
activity is lower than that of envelope-specific IgG activity
[119-122]. Similarly, the predominant SIV envelope-
specific antibodies in milk from lactating rhesus monkeys
are of the IgG isotype [123]. This is in accordance with
what has been observed in other mucosal compartments,
such as genital tract and saliva [119,120,124-128]. A few
studies explored the putative role of envelope-specific
antibodies present in breast milk of infected mothers to
prevent infant infection. Quantitative studies of HIV or
SIV envelope-specific binding antibodies did not reveal
any difference between transmitting and non-transmitting
mothers [129-131]. However, the neutralizing activity of
these antibodies was not analyzed in these studies. Two
recent studies made extensive comparisons of the neu-
tralizing and antibody-dependent cellular cytotoxicity
(ADCC) responses in breast milk and plasma from
African HIV-infected lactating women [122,132]. Al-
though lower in magnitude, the neutralizing and ADCC
activities in milk were directly correlated with those in
plasma and were primarily mediated by plasma-derived
IgG antibodies. Similarly, SIV-specific IgA antibodies
had limited neutralization potency compared to SIV-
specific IgG in SIV-infected rhesus monkeys [123]. This
suggests that IgA-mediated neutralizing and ADCC re-
sponses did not play a major role in preventing MTCT
transmission via breastfeeding. However, the capacity of
milk IgA to block HIV-1 transcytosis across epithelial
cells was not studied. Such a protective role, recently
reported for preventing vaginal and rectal infections in
animal models, cannot be excluded [133,134]. The pre-
venting role of IgG responses in mothers’ milk is diffi-
cult to explore due to the presence in newborns of high
physiological levels of passively acquired maternal IgG.
One study reported a higher magnitude of milk IgG-
mediated ADCC in HIV-1-infected women who did not
transmit HIV to their infants postnatally than in trans-
mitters [132]. This suggests that an efficient vaccine
should be able to induce a protective humoral response
that could be transferred also through breastfeeding.
Studies of passive immunization in newborn macaques:
sterilizing immunity
The development of MTCT models of SIV infection in
macaques has been very useful to evaluate the potential
of passively transferred antibodies to prevent infection.
V3, glycans :
2G12
PGT121
PGT128
V1V2, glycans :
PG9
PG16
PGT145
CD4bs :
b12
F105
VRC01
VRC03
NIH45-46G54W
HJ16
MPER :
2F5
10E8
MPER :
4E10
Figure 3 A model of the HIV-1 Env spike with selected HuMoNAbs Fabs bound to their conserved epitopes. Adapted with permission
from AAAS - Burton et al. [118]. The names of selected HuMoNAbs are underlined. The locations of their targeted epitopes are indicated in bold
and italic. The name of other HuMoNabs targeting similar epitopes is included [96,115-117,152,153].
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A first attempt of passive immunization of newborn
rhesus macaques with pooled sera from chronically SIV-
infected rhesus macaques has been shown to be protect-
ive from oral SIV exposure that mimics the mucosal
exposure occurring during perinatal and breast-milk HIV-
1 transmission (Table 2) [1]. However, the precise mech-
anism for the protection could not be established as no
neutralizing activity of these pooled sera could be detected
in vitro against the challenge virus. At about the same
time, the first HuMoNAbs, F105, 2F5, 4E10, 2G12 and
b12, were generated and characterized (Figure 3). F105
and b12 are directed against the CD4 binding site of
gp120 [135,136], 2G12 recognizes a conformational
carbohydrate-dependent epitope on gp120 [137], and
2F5 and 4E10 are directed against the MPER of gp41
[138,139]. To evaluate the capacity of these HuMoNAbs
to prevent HIV-1 infection, chimeric simian-human
immunodeficiency viruses (SHIV) were used. Because
the SIV and HIV envelope glycoproteins are too diver-
gent to analyze their sensitivity to NAbs, SHIV were
constructed based on a SIV backbone in which the SIV
env gene was replaced by an HIV-1 env gene. The first
SHIV constructs expressed the env gene of the T-cell
line laboratory-adapted (TCLA) HIV strain IIIB which is
highly neutralization-sensitive [140-143], but constructs
using env genes from primary HIV-1 isolates were sub-
sequently made, generating more pathogenic and more
neutralization-resistant SHIV viruses [144-147]. Using
the SHIV-macaque model, several studies have shown that
passive administration of high concentrations of various
Table 2 Studies of passive immunization in newborn macaques
Treatment Challenge Sterile
protection
References
Antibody (Route, Concentration) Infusion timing Virus Route
SIV hyperimmune serum
(SC, 20 mL/kg)
- Postnatal 2 days before challenge
SIVmac 251
(105 TCID50)
Oral
- 2/2
[1]
- Postnatal 2 days before challenge
and 5 and 12 days after challenge
- 4/4
- Postanatal 3 weeks after challenge - 0/3
- HIV immune globin (HIVIG)
(IV, 400 mg/kg)
Postnatal 24 hours
before challenge
SHIV89.6PD
(40 TCID50)
IV
- 0/3
[3]
- 2F5 (IV, 15 mg/kg) - 0/3
- 2G12 (IV, 15 mg/kg) - 0/3
- 2F5 / 2G12
(IV, 15 mg/kg of each)
- 0/3
- HIVIG/2F5/2G12
(IV, 400 mg/kg of HIVIG, 15 mg/kg
of each HuMoNAb)
- 3/6
F105/2G12/2F5
(IV, 10 mg/kg of each)
Pre- and postnatal 1–4 hours before
and 8 days after challenge
SHIVIIIB-vpu+
(10 AID50)
Oral 4/4 [4]
2G12/b12/2 F5
(IV, 10 mg/kg of each)
Postnatal 1 hour before and 8 days
after challenge
- SHIVIIIB-vpu+
(10 AID50)
Oral
- 2/2
[148]
- SHIV-89.6P
(15 AID50)
- 1/4
F105/2G12/2F5
(IV, 10 mg/kg of each)
- Postnatal 3–4 hours before
challenge and 8 days after challenge SHIVIIIB-vpu+
(10 AID50)
Oral
- 2/2
[149]
- Postnatal 1 hour and 8 days after
challenge
- 2/2
2G12/b12/2F5/4E10
(IV, 30 mg/kg of each except 4E10
at 11.5 mg/kg)
Postnatal 1 hour and 8 days after
challenge
SHIV-89.6P
(15 AID50)
Oral 2/4 [6]
2G12/2F5/4E10
(IM, 40 mg/kg of each)
Postnatal 1 hour and 8 days after
challenge
SHIV-89.6P
(15 AID50)
Oral 4/4 [150]
- 2G12/b12/2 F5/4E10
(IV, 30 mg/kg of each)
- Postnatal 1 hour and 8 days after
challenge
SHIV-89.6P
(15 AID50)
Oral
- 3/4
[151]
- Post natal 12 hours and 8 days after
challenge
- 1/4
- 2G12/2F5/4E10
(IM, 40 mg/kg of each)
- Postnatal 24 hours and 9 days post
challenge
- 0/4
TCID50: 50% tissue culture infectious dose; AID50: 50% animal infectious dose.
SC: subcutaneous; IV: intravenous; IM: intramuscular.
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combinations of the first-generation HuMoNAbs protected
neonatal rhesus macaques against high-dose intravenous
or oral challenge with SHIVs (Table 2) [3,4,6,148-151].
These results provided the proof-of-concept that anti-
bodies can prevent infection. However the current SHIV
models, which include only a few HIV Envs, provide data
that are limited to protection against a restricted number
of isolates and therefore has limitations when considering
the high diversity of HIV-1 isolates. In addition, these
studies highlighted the importance of the timing of admin-
istration, since HuMoNAbs must be present at the time of
viral challenge or only a few hours later to prevent the es-
tablishment of infection (sterilizing immunity) of the new-
born macaques (Table 2) (Figure 4A). There was no
protection when antibodies were administered more
than 12 hours post-virus inoculation (Figure 4B). Re-
cently, the association of several technological advances
allowed the identification of new second-generation
HuMoNAbs (particularly the PG, PGT and VRC series)
that are tenfold to 100-fold more potent in vitro than
the first-generation HuMoNAbs used in passive immu-
nization studies [96,115-117,152,153] (Figure 3). One of
these antibodies, PGT121, was able to mediate steriliz-
ing immunity against high-dose mucosal viral challenge
in adult rhesus macaques at serum concentrations that
were significantly lower than those observed in previous
studies [154]. In addition, Klein et al. re-examined the
possibility to use antibody transfer as a therapeutic mo-
dality [155]. Using a humanized mice model and combi-
nations of these new NAbs that target complementary
1st generation 
HuMo NAbs
A
B
C
1st generation 
HuMo NAbs
2nd generation 
HuMo NAbs
Time
Figure 4 Studies of passive immunization in newborn macaques. A. Passive administration of high concentrations of various combinations
of the first-generation HuMoNAbs (b12, 2G12, 2F5, 4E10, F105) (white arrow) before or simultaneously with intravenous or oral challenge with
SHIVs (green arrow) protected neonatal rhesus macaques against infection: there was no infection [4,149,150]. B. There was no protection when
the first-generation HuMoNAbs (white arrow) were administered more than 12 hours post-virus inoculation (green arrow) [151]. C. New second-
generation HuMoNAbs (PG-, PGT-, VRC-series) that are 10- to 100-fold more potent in vitro than the first-generation HuMoNAbs have been
identified [96,115-117,152,153]. It would be interesting to re-evaluate the potential protective potency of NAbs in newborn macaques when
administered either before or after (white arrow) viral exposure (green arrow).
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sites on the HIV-1 spike protein, they showed that these
antibodies could effectively control HIV-1 infection and
suppress viral load to levels below detection. Given
these new data, it would be interesting to evaluate the
protective potency of these new NAbs in newborn ma-
caques for both pre-exposure and post-exposure
prophylaxies (Figure 4C). Indeed, a recent study of pas-
sive administration of neutralizing IgG (including the
HuMoNAb b12) at levels insufficient to block infection
to newborn macaques before oral challenge with a SHIV
virus has shown that immunized macaques rapidly de-
veloped NAbs and had a significantly reduced plasma
viremia [156]. This supports the use of NAbs to aug-
ment B cell responses and viral control in perinatal set-
tings, although further studies are needed to understand
the mechanisms underlying their beneficial effects.
Prevention of mother to child transmission :
immunoprophylaxis
MTCT of HIV-1 infection remains a significant problem
in developing countries. Antiretroviral (ARV) prophy-
laxis can reduce the number of infections, but it does
not eliminate the transmission risk. ARV efficacy is
highly dependent on strict adherence to daily adminis-
tration that is difficult to achieve for many women/ba-
bies. Even with optimal prophylaxis, infections occur at
a rate of 1 to 5% at 6 months of age in infants of HIV-1
infected mothers who breastfeed [157]. Additional inter-
ventions that ideally do not rely on daily adherence to
prevent transmission during prolonged breastfeeding
need to be identified [158]. The use of an anti-HIV-1 pas-
sive immunization approach in addition to ARV prophy-
laxis could provide additional protection and deserves to
be explored.
Passive immunization experiments of rhesus macaques
have proven that NAbs can protect from MTCT. In
humans, there are only 2 phase III studies of passive
immunization to prevent MTCT that have been con-
ducted. Both used polyclonal hyperimmune globulin
preparations from HIV-1-infected donors. The first
study was conducted in 1993–1997 in the United States
in a non-breastfeeding population of HIV-1 infected
pregnant women receiving zidovudine prophylaxis [159].
The second was conducted in 2004–2006 in Uganda in
breastfeeding pregnant mothers receiving single-dose
nevirapine [160]. Although the infusion of HIV hyper-
immune preparations was proven to be safe, no add-
itional benefit of these polyclonal preparations compared
to antiretroviral treatment alone was shown in these two
studies. However, it may be possible that polyclonal prepa-
rations did not contain enough NAbs specificities able to
provide sterilizing immunity. The use of HuMoNAbs may
be more appropriate to reach this goal and it was pro-
posed to use them in human clinical trials [161,162].
However, several of the first-generation antibodies (b12,
2F5 and 2G12) were found ineffective or only partly effect-
ive against non-B viruses, particularly toward a panel of
clade C Env-pseudotyped viruses derived from primary
isolates of South African infected children and conse-
quently did not seem to be relevant to prevent MTCT in
populations where non-B viruses predominate [163]. In
contrast, the second-generation of broadly HuMoNAbs
directed against quaternary epitopes (PG9, PG16), the
CD4bs epitopes (VRC01, NIH45-46G54W) and V3 glycan-
dependent epitopes (PGT121, PGT128) were recently
found to be able to neutralize most of HIV-1 non-B vari-
ants transmitted through breastfeeding [89,164-166].
Similarly, by comparing functional properties of CRF01-
AE variants transmitted perinatally to infants with those
of their chronically infected mothers, we recently found
that all the transmitted variants were highly sensitive to
both PG9 and PG16, significantly more sensitive than the
maternal variants [95]. Together, these data would suggest
that this new generation of HuMoNAbs could be efficient
in passive immunization strategies. HIV prevention trials
in African breastfed infants using the antibody HuMoNAb
VRC01 are currently considered [167].
Conclusions
There are strong evidences for a selective advantage of
the HIV-1 variants that are transmitted from the mother
to the infant in the presence of maternal HIV-1-specific
antibodies. An association between presence or titers of
NAbs toward different HIV-1 strains and a lower rate of
mother-to-child transmission has been found in several
studies, suggesting that some NAbs could contribute to
protection toward neonatal infection. Together, these data
suggest that some neutralizing specificities might be pro-
tective and, in case of transmission, that the transmitted
variants escape these specificities. Dissecting the antibody
specificities that mediate protection toward MTCT of
HIV-1 could provide important clues for identification of
correlates of protection that would be useful for vaccine
development. Experiments of passive immunization in
newborn macaques have shown that first-generation
HuMoNAbs can fully protect against SHIV infection, pro-
viding additional proof that NAbs can inhibit MTCT. The
recent identification of highly potent second-generation
HuMoNAbs provides a new opportunity to evaluate the ef-
ficacy of passive immunization to prevent mother-to-child
transmission of HIV-1.
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